Video: India Clears Two Coronavirus Vaccines for Emergency Use

Soon after ample examination, the C.D.S.C.O. has determined to accept the suggestions of the Professional Committee and, accordingly, vaccines of M/s Serum and Bharat Biotech are remaining authorized for limited use in emergency circumstances and permission is remaining granted to M/s Cadila Healthcare for perform of Phase three clinical trials in India. The Phase three efficacy trial was initiated in India in 25,800 volunteers and, to date, somewhere around 22,500 participants have been vaccinated across the nation and the vaccine has been discovered to be harmless as per the information readily available to date.